Monosomy - 7 Studies Found

Completed : Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
:
  • MDS
  • AML

: 2008-09-26
: Drug: lenalidomide Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increa
Completed : Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
: Acute Myeloid Leukemia
: 2012-02-13
: Drug: sorafenib, vorinostat and bortezomib Escalating dose cohorts of sorafenib, vorinostat and bortezom
Active, not recruiting : Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
: Leukemia
: 2007-11-02
:
  • Biological: anti-thymocyte globulin

Terminated : Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
:
  • Myelodysplastic Syndromes
  • Acute Myelogenous Leukemia

: 2008-07-17
: Drug: lenalidomide p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
Terminated : LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
: AML
: 2010-07-29
: Drug: Lenalidomide Initial dose of oral lenalidomide is 10
Completed : A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
:
  • Acute Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic
    : 2009-12-17
    : Other: Withdrawal of immunosuppression and donor lymphocyte infusion Intervention will involve fast with
Terminated : Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
:
  • Myelodysplastic Syndromes
  • Acute Myelogenous Leukemia

: 2009-06-17
:
  • Drug: Azacitidine 75 mg/m²